Latest / Flash Stock Reports (Video)
CMPX Dropped to $1.85: FDA Delay vs $180M Cash
CMPX stock analysis: $180M cash runway backstops FDA delay — full valuation breakdown
👉 Want this level of research on ANY COMPANY IN THE WORLD... for FREE? Check us out at: https://flash.stocksentinel.ai/?utm_source=rss_video&utm_medium=explainer_video&utm_campaign=freja_and_friends
In this deep dive, we break down Compass Therapeutics, Inc. (CMPX) and its clinically validated antibody pipeline following recent FDA feedback on lead asset Tovecimig. With an Enterprise Value of $153 million backstopped by $180 million in cash runway into 2028, the key question for investors is whether clinical…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.